204 related articles for article (PubMed ID: 32176735)
21. Molecular basis of the attenuated phenotype of human APOBEC3B DNA mutator enzyme.
Caval V; Bouzidi MS; Suspène R; Laude H; Dumargne MC; Bashamboo A; Krey T; Vartanian JP; Wain-Hobson S
Nucleic Acids Res; 2015 Oct; 43(19):9340-9. PubMed ID: 26384561
[TBL] [Abstract][Full Text] [Related]
22. Genetic inhibitors of APOBEC3B-induced mutagenesis.
Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
[TBL] [Abstract][Full Text] [Related]
23. Associations between the single nucleotide polymorphisms of APOBEC3A, APOBEC3B and APOBEC3H, and chronic hepatitis B progression and hepatocellular carcinoma in a Chinese population.
He X; Xu H; Wang X; Wu J; Niu J; Gao P
Mol Med Rep; 2019 Sep; 20(3):2177-2188. PubMed ID: 31322199
[TBL] [Abstract][Full Text] [Related]
24. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
25. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism.
Chen TW; Lee CC; Liu H; Wu CS; Pickering CR; Huang PJ; Wang J; Chang IY; Yeh YM; Chen CD; Li HP; Luo JD; Tan BC; Chan TEH; Hsueh C; Chu LJ; Chen YT; Zhang B; Yang CY; Wu CC; Hsu CW; See LC; Tang P; Yu JS; Liao WC; Chiang WF; Rodriguez H; Myers JN; Chang KP; Chang YS
Nat Commun; 2017 Sep; 8(1):465. PubMed ID: 28878238
[TBL] [Abstract][Full Text] [Related]
26. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
27. AID, APOBEC3A and APOBEC3B efficiently deaminate deoxycytidines neighboring DNA damage induced by oxidation or alkylation.
Diamond CP; Im J; Button EA; Huebert DNG; King JJ; Borzooee F; Abdouni HS; Bacque L; McCarthy E; Fifield H; Berghuis LM; Larijani M
Biochim Biophys Acta Gen Subj; 2019 Nov; 1863(11):129415. PubMed ID: 31404619
[TBL] [Abstract][Full Text] [Related]
28. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
[TBL] [Abstract][Full Text] [Related]
29. APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
Yamazaki H; Shirakawa K; Matsumoto T; Kazuma Y; Matsui H; Horisawa Y; Stanford E; Sarca AD; Shirakawa R; Shindo K; Takaori-Kondo A
PLoS One; 2020; 15(1):e0223463. PubMed ID: 31914134
[TBL] [Abstract][Full Text] [Related]
30. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.
Akre MK; Starrett GJ; Quist JS; Temiz NA; Carpenter MA; Tutt AN; Grigoriadis A; Harris RS
PLoS One; 2016; 11(5):e0155391. PubMed ID: 27163364
[TBL] [Abstract][Full Text] [Related]
31. Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells.
Maruyama W; Shirakawa K; Matsui H; Matsumoto T; Yamazaki H; Sarca AD; Kazuma Y; Kobayashi M; Shindo K; Takaori-Kondo A
Biochem Biophys Res Commun; 2016 Sep; 478(3):1466-71. PubMed ID: 27577680
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1.
Ooms M; Krikoni A; Kress AK; Simon V; Münk C
J Virol; 2012 Jun; 86(11):6097-108. PubMed ID: 22457529
[TBL] [Abstract][Full Text] [Related]
33. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population.
Göhler S; Da Silva Filho MI; Johansson R; Enquist-Olsson K; Henriksson R; Hemminki K; Lenner P; Försti A
J Cancer Res Clin Oncol; 2016 Jan; 142(1):273-6. PubMed ID: 26320772
[TBL] [Abstract][Full Text] [Related]
34. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB.
Periyasamy M; Singh AK; Gemma C; Farzan R; Allsopp RC; Shaw JA; Charmsaz S; Young LS; Cunnea P; Coombes RC; Győrffy B; Buluwela L; Ali S
Oncogene; 2021 Feb; 40(6):1077-1090. PubMed ID: 33323971
[TBL] [Abstract][Full Text] [Related]
35. APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts.
Niavarani A; Currie E; Reyal Y; Anjos-Afonso F; Horswell S; Griessinger E; Luis Sardina J; Bonnet D
PLoS One; 2015; 10(3):e0120089. PubMed ID: 25807502
[TBL] [Abstract][Full Text] [Related]
36. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection.
Abe H; Ochi H; Maekawa T; Hatakeyama T; Tsuge M; Kitamura S; Kimura T; Miki D; Mitsui F; Hiraga N; Imamura M; Fujimoto Y; Takahashi S; Nakamura Y; Kumada H; Chayama K
Hepatol Res; 2009 Dec; 39(12):1159-68. PubMed ID: 19788695
[TBL] [Abstract][Full Text] [Related]
37. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
38. Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
Zhao K; Zhang Q; Flanagan SA; Lang X; Jiang L; Parsels LA; Parsels JD; Zou W; Lawrence TS; Buisson R; Green MD; Morgan MA
Mol Cancer Res; 2021 Sep; 19(9):1571-1582. PubMed ID: 34045311
[TBL] [Abstract][Full Text] [Related]
39. Unraveling the Enzyme-Substrate Properties for APOBEC3A-Mediated RNA Editing.
Kim K; Shi AB; Kelley K; Chen XS
J Mol Biol; 2023 Sep; 435(17):168198. PubMed ID: 37442413
[TBL] [Abstract][Full Text] [Related]
40. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
Vural S; Simon R; Krushkal J
Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
